在基中准殖民地刺激因子-1受体:划出癌症免疫治疗的界限
Zahra Azhar1, Richard P Grose1, Afsheen Raza2
1Centre of Tumour Biology, Barts Cancer Institute, Queen Mary University of London, EC1M 6BQ London, UK.
Exploration of targeted anti-tumor therapy
|September 15, 2023
概括
针对殖民地刺激因子-1受体 (CSF1R) 的小分子抑制剂被分析为癌症疗法. 由于它们的结构稳定性和结合亲和力,DCC-3014和ARRY-382显示出显著的潜力.
科学领域:
- 药用化学 医学化学
- 结构生物学 结构生物学
- 计算机化药物发现技术
背景情况:
- 殖民地刺激因子-1受体 (CSF1R) 是癌症免疫疗法的新型预测生物标志物.
- 针对CSF1R的小分子抑制剂正在为癌症疗法进行临床开发.
研究的目的:
- 通过小分子抑制剂来划分基于结构的CSF1R抑制.
- 通过结构-活性关系分析,识别癌症治疗药物的潜在化合物.
主要方法:
- 在分子操作环境 (MOE) 中使用诱导合适对接协议进行*in silico*建模.
- 使用了CSF1R激酶的3DX射线结晶结构 (PDB ID: 4R7H).
- 结合了七种已知的CSF1R抑制剂 (edicotinib,DCC-3014,ARRY-382,BLZ-945,chiauranib,dovitinib,sorafenib) 并分析了结合相互作用.
主要成果:
- 所有七种抑制剂都与Met637相互作用,埃迪科提尼布的选择性较低.
- 抑制剂通过与Asp797 (DFG动机) 相互作用和/或阻碍Glu633-Lys616盐桥来稳定CSF1R,使其处于自身抑制的形状.
- DCC-3014,ARRY-382,BLZ-945和sorafenib显示了与CSF1R激酶的最低结合能量.
结论:
- 皮里米丁是有效的CSF1R抑制剂,与关键的CSF1R残留物相互作用.
- DCC-3014和ARRY-382具有显著的制药潜力,其特点是高结构稳定性和亲和力.
相关概念视频
Tumor Immunotherapy
554
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
554
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
Regulation of Hematopoietic Stem Cells
3.2K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
3.2K
Differentiation of Common Myeloid Progenitor Cells
3.2K
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
3.2K
Mitogens and the Cell Cycle
6.5K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K


